Treatment of Chronic Inflammatory
Demyelinating Polyneuropathy With High-Dose
Intermittent Intravenous Methylprednisolone
Arch Neurol. 2005;62:249-254.
ABSTRACT
|
|
Background Chronic inflammatory
demyelinating polyradiculoneuropathy
(CIDP) causes progressive disability due to weakness
but responds to immunomodulating
medication, including oral prednisone and
intravenous (IV) immunoglobulin (IVIg). However,
there is no consensus on initial therapy,
and both of these treatments have
drawbacks with long-term treatment.
Objective To review the efficacy and
safety of high-dose, intermittent IV
methylprednisolone (IVMP) as initial and long-term
maintenance therapy for patients with CIDP.
Design A retrospective medical record
review between 1992 and 2003 of outcomes
in CIDP, comparing patients in 3 cohorts
depending on whether their primary treatment was
IVMP, IVIg, or oral immunosuppression
with prednisone or cyclosporine.
Setting Washington University
Neuromuscular Disease Center (St Louis,
Mo), outpatient and inpatient records.
Patients Patients with clinical and
electrophysiologic evidence of CIDP were
identified. Of 57 patients, 39 had sufficient
data for full analysis.
Main Outcome Measures Quantitative muscle
testing with a handheld dynamometer.
Medication profiles and adverse effects
were also recorded.
Results There was no significant
difference in the mean improvement in
quantitative muscle testing at 6 months or at
the last clinic visit (an average of 4.5 years
later) among the 3 groups. Fewer patients
treated with oral immunosuppression
improved at 6 months, but at the last visit, 81% to
88% improved in all 3 groups. Less weight
gain and fewer cushingoid features
affected patients treated with IVMP (19%) compared
with patients treated with oral
prednisone (58%).
Conclusions Treatment of patients with
CIDP using high-dose intermittent IVMP
results in improved strength equal to that
with IVIg and oral prednisone. The frequency
of occurrences of weight gain and
cushingoid features with IVMP is less than
that with oral prednisone. Intravenous
methylprednisolone should be considered
for initial and long-term therapy in CIDP when
patients have disability due to weakness.
INTRODUCTION
Chronic inflammatory demyelinating polyneuropathy
(CIDP) causes significant disability due
to weakness but often improves after
immunomodulating treatment. The primary goal of
therapy is improved strength and
functional ability. Improvements in pain, sensory
loss, and gait disorders are other goals of
therapy. At present, there are no
guidelines concerning the initial choice of therapy.
Corticosteroids, plasma exchange, and
intravenous (IV) immunoglobulin (IVIg)
have all been shown to have efficacy. The choice of
therapy depends on several factors,
including disease severity, concomitant
illnesses, adverse-effect profile, potential drug
interactions, venous access, age-related
risks, and cost of treatment.1
Corticosteroids have been used to treat CIDP for
almost 50 years. Controlled trials have
supported the initial impression of efficacy,2-3
and treatment with prednisone is now accepted
as a first- or second-line therapy in
CIDP. Although there is no standard regimen,
corticosteroid treatment of CIDP often begins
with daily oral prednisone, at high doses
of up to 1 mg/kg.4
When improved strength is noted, usually
after 1 to 3 months, a slow taper in total
dose is begun and an effort is made to
administer the drug on alternate days.
Recurrence of symptoms during the taper necessitates
reinstitution of higher doses of prednisone or
the introduction of an alternative agent.
A major drawback to long-term oral
corticosteroid use is the common occurrence of
adverse effects, including weight gain,
cushingoid appearance, hyperglycemia,
peptic ulcer disease, insomnia, infection,
cataracts, and osteoporosis.1,
5 Alternate-day corticosteroid treatment
probably has fewer adverse effects than
daily dosing.
The mechanism of action of steroids is complex
and likely involves multiple effects
brought about by the activation of the
glucocorticoid receptor.6
The glucocorticoid receptor binds to
glucocorticoid-responsive elements
located in the promoter regions of specific genes or
to other nuclear transcription factors and can
activate or inhibit gene transcription.
Although prednisone has an elimination half-life
of 1.5 to 4 hours, some of its effects might
last for days because of changes in gene
expression and protein synthesis.5-6
We began using high-dose intermittent IV
methylprednisolone (IVMP) as initial and
long-term maintenance therapy for many
patients with CIDP in 1992 in an attempt to find an
alternative treatment regimen without the
problems associated with long-term daily
steroids. We now report a retrospective review of
all CIDP patients treated in the
Washington University Neuromuscular
Disease Center (St Louis, Mo) between 1992 and 2003.
We compared patients treated with IVMP,
IVIg, and long-term oral immunosuppression.
We evaluated the efficacy of each treatment by
examining changes in quantitative
strength measures, medication history, and adverse
effects or complications with each type of
treatment.